| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014064492 |
| P356 | DOI | 10.1186/AR2878 |
| P932 | PMC publication ID | 3003532 |
| P698 | PubMed publication ID | 20003285 |
| P5875 | ResearchGate publication ID | 40681150 |
| P50 | author | Ingrid E Lundberg | Q38324999 |
| Elisabet Svenungsson | Q40131460 | ||
| Julia Simard | Q42647701 | ||
| Susanne Pettersson | Q57832401 | ||
| Anders Larsson | Q59163549 | ||
| P2093 | author name string | Iva Gunnarsson | |
| Johanna Gustafsson | |||
| Kerstin Elvin | |||
| Lars-Olof Hansson | |||
| Guo-Zhong Fei | |||
| Sonia Möller | |||
| Ola Börjesson | |||
| P2860 | cites work | Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers? | Q28219261 |
| A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus | Q28258975 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. | Q33492107 | ||
| Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response? | Q33564386 | ||
| Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies | Q33578658 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study | Q34017775 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| Inflammation as a cardiovascular risk factor | Q35789860 | ||
| Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus | Q35954549 | ||
| Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis | Q36059617 | ||
| Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus | Q36806527 | ||
| von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. | Q37112364 | ||
| Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus | Q37367326 | ||
| Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. | Q37681307 | ||
| Mortality in systemic lupus erythematosus | Q38467155 | ||
| Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. | Q38479125 | ||
| Measurement of systemic lupus erythematosus activity in clinical research | Q39653459 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 | ||
| Circulating cell adhesion molecules and death in patients with coronary artery disease | Q40686123 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study | Q41662827 | ||
| Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population | Q42037849 | ||
| Risk factors for cardiovascular disease in systemic lupus erythematosus | Q43767819 | ||
| Brachial endothelial function is impaired in patients with systemic lupus erythematosus | Q43884850 | ||
| Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study | Q44383942 | ||
| Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study | Q44652580 | ||
| Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. | Q45147984 | ||
| Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups | Q46660881 | ||
| Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. | Q47719646 | ||
| Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study | Q47945285 | ||
| High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. | Q50755801 | ||
| Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. | Q52094951 | ||
| Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? | Q53704347 | ||
| TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. | Q53923210 | ||
| Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus | Q57216969 | ||
| von Willebrand factor and coronary heart disease. Prospective study and meta-analysis | Q57416365 | ||
| Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus | Q58190241 | ||
| Coexistence of Anti-Phospholipid Antibodies and Endothelial Perturbation in Systemic Lupus Erythematosus Patients With Ongoing Prothrombotic State | Q58421342 | ||
| Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus | Q60692382 | ||
| Risk factors for coronary artery disease in patients with systemic lupus erythematosus | Q67586359 | ||
| Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients form a defined population | Q68035493 | ||
| Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity | Q71160332 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus | Q79376053 | ||
| Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus | Q80979060 | ||
| Carotid atherosclerosis and endothelial cell adhesion molecules as predictors of long-term outcome in chronic hemodialysis patients | Q81567771 | ||
| Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome | Q93879705 | ||
| P433 | issue | 6 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| circulatory system | Q11068 | ||
| patient | Q181600 | ||
| P304 | page(s) | R186 | |
| P577 | publication date | 2009-12-10 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study | |
| P478 | volume | 11 |
| Q36746168 | 17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice |
| Q35878289 | Acute coronary events |
| Q38885685 | Anti-phospholipid Antibodies and Smoking: An Overview |
| Q39017583 | Association between ischemic heart disease and systemic lupus erythematosus-a large case-control study |
| Q35525108 | Atherosclerosis in systemic lupus erythematosus |
| Q58190143 | Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus |
| Q36153524 | Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry |
| Q37330468 | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. |
| Q43885994 | Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q38554636 | Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q45843374 | Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus |
| Q33404418 | Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays |
| Q37456307 | Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials |
| Q35557372 | Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation |
| Q49072554 | Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. |
| Q38162490 | Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus |
| Q38654271 | Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus? |
| Q34409903 | Early vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk |
| Q37853794 | Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy |
| Q57753999 | Evaluation of Impact of Interferon-Induced Helicase C Domain-Containing Protein 1 Gene in Egyptian Systemic Lupus Erythematosus Patients and its Relationship With Vascular Manifestations of the Disease |
| Q33570432 | Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls |
| Q83115423 | Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus |
| Q36031383 | Frequency, clinical implication and prognostic value of lymphopenia in systemic lupus erythematosus: case-control study |
| Q35645573 | Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up |
| Q33801351 | IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). |
| Q36606667 | Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus |
| Q39367860 | Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation. |
| Q37782589 | Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin |
| Q36932166 | Is preclinical autoimmunity benign?: The case of cardiovascular disease |
| Q50624271 | Left ventricular remodeling and dysfunction in systemic lupus erythematosus: a three-dimensional speckle tracking study. |
| Q48328781 | Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study |
| Q42149294 | Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice. |
| Q37363894 | Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations |
| Q41744502 | Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q35998510 | Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention |
| Q51076609 | Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus. |
| Q48434991 | Physical activity in patients with systemic lupus erythematosus and matched controls |
| Q51366906 | Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. |
| Q38899360 | Platelet-Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus |
| Q42771406 | Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge. |
| Q37704239 | Rapidly progressive coronary artery disease as the first manifestation of antiphospholipid syndrome. |
| Q33766242 | Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study |
| Q26771476 | Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies |
| Q43468721 | Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center |
| Q37033345 | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention |
| Q35530248 | Systemic lupus erythematosus and thrombosis |
| Q36308509 | The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis |
| Q37817582 | The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? |
| Q39283399 | The evolving concept of SLE comorbidities. |
| Q52593839 | The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective G |
| Q40910621 | The vascular phenotype of children with systemic lupus erythematosus |
| Q34273836 | Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients |
| Q38663003 | Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. |
| Q33402792 | von Willebrand factor: more than a regulator of hemostasis and thrombosis |
Search more.